3상모집 중

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

연구 개요

The main purpose of this study is to assess how well the study drug (JNJ-42847922) works (efficacy) compared with placebo in improving depressive symptoms in participants with major depressive disorder (\[MDD\], a common mood disorder that causes a lasting feeling of sadness and a loss of interest in everyday activities) in double-blind treatment phase. Further, to evaluate long-term safety and tolerability of JNJ-42847922 in participants with MDD in the open label treatment phase.

스폰서
리드: 얀센(J&J)
적응증
Depressive Disorder, Major
중재
Seltorexant, Placebo
목표 등록
600
시작일
2026-04-30
완료(예정)
2029-05-03

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.